Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Annals of Gastroenterology|March 7, 2018
Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumorsPieter-Jan Cuyle, Hans Prenen
Acta Clinica Belgica|December 6, 2016
Current and future biomarkers in the treatment of colorectal cancerPieter-Jan Cuyle, Hans Prenen
Targeted Oncology|June 5, 2020
Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature ReviewAn-Katrien Seghers, Pieter-Jan Cuyle, Eric Van Cutsem
Journal of Drug Assessment|June 12, 2018
Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgeryPieter-Jan Cuyle, Anke Engelen, Veerle Moons, et al.
Clinical Nuclear Medicine|May 25, 2021
68Ga-DOTATATE PET/CT Distinguishes Neuroendocrine Tumor Mesenteric Lymph Node Metastasis From an Extensive IgG4-Positive Fibrosis Surrounding ItNiloefar Ahmadi Bidakhvidi, Pieter-Jan Cuyle, Xavier Sagaert, et al.
Nature Clinical Practice. Urology|August 4, 2007
Urea-splitting urinary tract infection contributing to hyperammonemic encephalopathyMaarten Albersen, Steven Joniau, Hein Van Poppel, et al.
United European Gastroenterology Journal|June 12, 2014
Comparison of six different calprotectin assays for the assessment of inflammatory bowel diseaseDelphine Labaere, Annick Smismans, August Van Olmen, et al.
Acta Clinica Belgica|October 31, 2019
Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assayBea Van den Poel, Sarah Gils, Isabel Micalessi, et al.
Journal of Neuroendocrinology|November 28, 2024
Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data 2010-2019Marlies Maly, Eduard Callebout, Suzane Ribeiro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2024
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 studyAtsuo Takashima, Pilar García-Alfonso, Raimundo Manneh, et al.
Pageof 2